Retatrutide Guide
Retatrutide: what trials report so far on the triple agonist
3
hormone receptors targeted
~24%
phase 2 weight loss, top dose, 48 wks
Not yet
approved; phase 3 ongoing
Retatrutide is not an approved medication: it is an investigational once-weekly injection in late-stage trials, and everything known about it comes from that trial program. It targets three receptors at once (GLP-1, GIP, and glucagon), and its phase 2 results made headlines: an average of roughly 24% body-weight loss at the top dose over 48 weeks, the largest reported for any incretin drug at the time. The side effects reported so far look familiar rather than novel: dose-dependent GI effects led by nausea, concentrated during escalation, plus a heart-rate increase that trials monitored specifically. Phase 3 will decide the fuller picture.
Highlights
Key takeaways
- 01
Retatrutide is investigational. It is not approved, not available by prescription, and everything below reflects trial reports, not established prescribing information.
- 02
The triple mechanism adds glucagon receptor activity to the familiar GLP-1 plus GIP pairing, aiming to raise energy expenditure alongside appetite suppression.
- 03
Phase 2 (48 weeks): average weight loss around 17% at 8 mg and 24% at 12 mg, with the curve still descending at trial's end.
- 04
Reported side effects were mostly mild to moderate GI events (nausea, diarrhea, vomiting, constipation), dose-dependent and concentrated during escalation, echoing the class pattern.
- 05
A modest average heart-rate increase was observed, peaking mid-trial and attenuating; phase 3 tracks cardiovascular measures closely.
- 06
If it wins approval, expect the same playbook this class always needs: slow titration, food mechanics, hydration, and a symptom log.
Retatrutide at a glance: what trials have reported
| Aspect | What phase 2 reported | Context |
|---|---|---|
| Weight loss | ~17% at 8 mg, ~24% at 12 mg over 48 wks | Curves not yet plateaued at trial end |
| Common side effects | Nausea, diarrhea, vomiting, constipation | Dose-dependent, mostly mild to moderate |
| When effects clustered | During dose escalation | Slower escalation arms reported less |
| Heart rate | Modest average increase, attenuating over time | Monitored specifically in phase 3 |
| Discontinuation over AEs | ~6–16% by dose arm | Highest at fastest escalations |
| Status | Phase 3 (TRIUMPH program) ongoing | No approval anywhere yet |
Drawn from the published phase 2 obesity trial (48 weeks) and program communications. Investigational data changes as trials read out; nothing here is prescribing information or a basis for seeking the compound outside a trial.
What is retatrutide, and how is it different?
Retatrutide activates three metabolic hormone receptors at once: GLP-1 (appetite, gastric pace), GIP (the second incretin tirzepatide added), and glucagon, whose receptor activity is associated with increased energy expenditure. The design goal is to pair eating less with burning somewhat more.
It is a once-weekly injection developed by the maker of tirzepatide, and it is frequently discussed as the next step in the incretin sequence: semaglutide's single agonism, tirzepatide's dual, retatrutide's triple.
What did phase 2 actually show?
In the published 48-week phase 2 obesity trial, average weight loss reached roughly 17% at 8 mg and about 24% at 12 mg, against roughly 2% on placebo, with the treatment curves still descending when the trial ended. Those are the numbers that put the molecule on magazine covers.
Phase 2 also means a few hundred participants per arm and a design tuned to find doses, not to settle safety. The phase 3 program (TRIUMPH) is what turns headline numbers into an approvable, characterized medication.
What side effects did the trials report?
The reported profile reads like the class: gastrointestinal events led (nausea, diarrhea, vomiting, constipation), they scaled with dose, clustered during escalation, and were mostly mild to moderate. Slower escalation visibly softened them, which is why the phase 3 protocols titrate gently.
The distinct watch-item is heart rate: a modest average increase, peaking around mid-trial and attenuating afterward, consistent with glucagon-receptor activity. It is the main reason cardiovascular monitoring sits at the center of the phase 3 program.
Cautions the trials flagged
Beyond the class-standard GI escalation story, trial communications emphasized heart-rate monitoring, and the incretin-class cautions (pancreatitis vigilance, gallbladder risk with rapid loss, the rodent thyroid C-cell warning) are expected to carry over into any label.
The practical caution today is simpler: retatrutide is not purchasable legitimately. Products sold online as retatrutide are unregulated gray-market chemicals with no manufacturing oversight, and using them means dosing an investigational triple agonist with no clinical support. That is a genuinely bad risk trade.
Worth knowing before the headlines sweep you up
- Retatrutide is investigational: no approval, no prescribing information, no pharmacy access
- Online retatrutide is gray-market chemistry with zero oversight
- Trial GI effects were real, dose-dependent, and escalation-focused
- Heart-rate increases are a specific phase 3 watch-item
- Class cautions (pancreatitis, gallbladder, thyroid C-cell) are expected to apply
- Approved options exist today; waiting untreated for a future drug has its own costs
When could it arrive, and what should you do now?
Phase 3 readouts and regulatory submissions will set the timeline; approvals, if they come, land after that. Until then, the approved incretins (semaglutide, tirzepatide) are the real options, and they are strong ones.
If retatrutide eventually matters to you, the preparation is unglamorous: get your routine, protein, training, and tracking habits solid on whatever you and your prescriber choose now. Whatever the future molecule, the habits transfer completely.
FAQ
Frequently asked questions
What is retatrutide?
An investigational once-weekly injection that activates GLP-1, GIP, and glucagon receptors together. Phase 2 reported up to ~24% average weight loss over 48 weeks; phase 3 trials are ongoing and it is not approved anywhere yet.
What are retatrutide's side effects?
Trials so far report the familiar incretin list: dose-dependent nausea, diarrhea, vomiting, and constipation concentrated during escalation, mostly mild to moderate, plus a modest average heart-rate increase that phase 3 is monitoring closely.
When will retatrutide be available?
Only after phase 3 readouts and regulatory review; no approval exists yet. Timelines depend on the TRIUMPH program's results and submissions.
Can I buy retatrutide online?
Not legitimately. Anything sold as retatrutide today is an unregulated gray-market product with no manufacturing oversight or clinical support, which is a serious safety risk on a potent investigational triple agonist.
Track your GLP-1 journey on one quiet line.
Log your shot, injection site, meals, and side-effect severity together, and walk into your next appointment with a week-by-week picture instead of a guess.
Sources
- 1.Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (phase 2, 48 weeks). NEJM 2023. Find on PubMed ↗
- 2.TRIUMPH phase 3 program registrations and sponsor communications. Find on PubMed ↗
- 3.Published commentary on glucagon-receptor activity, energy expenditure, and heart-rate observations in incretin therapeutics. Find on PubMed ↗
This guide is for general education and is not medical advice. It doesn't account for your personal medical history, other medications, or your individual situation, and it doesn't replace a conversation with your doctor or pharmacist. Do not start, stop, or change the dose of GLP-1 or any medication based on what you read here. If you think you have a medical emergency, call your local emergency number. DoseLog is a tracking app; drug and company names are used factually under nominative fair use, and DoseLog is not affiliated with, endorsed by, or sponsored by any manufacturer mentioned.
Keep reading
Orforglipron Guide
Orforglipron: the once-daily GLP-1 pill, and what trials report
GLP-1 Comparison Matrix
Every GLP-1 medication compared: the full matrix
Wegovy vs Zepbound Guide
Wegovy vs Zepbound: the head-to-head, honestly read
Ozempic vs Mounjaro Guide
Ozempic vs Mounjaro: the diabetes head-to-head, honestly read